Australia Stock Exchange release from ANTISENSE THERAP : ANP to participate in development of DMD Guidance for FDA
23/08/2021 23:31
Australia Stock Exchange release from ANTISENSE THERAP ANP.AX : ANP to participate in development of DMD Guidance for FDA
Recent news on Percheron Therapeutics
See all newsBrief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Brief: Percheron Therapeutics Receives Firm Commitments For A$2.3 Million Institutional Placement
Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
Brief: Percheron Therapeutics Says James Garner To Step Down As CEO And Managing Director